Erratum to: The Rituximab Biosimilar CT-P10 in Rheumatology and Cancer: A Budget Impact Analysis in 28 European Countries (Adv Ther, 10.1007/s12325-017-0522-y)

3Citations
Citations of this article
8Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

The authors of this manuscript have noticed a mistake since publication of their manuscript. In the original publication, the ‘Total RTX consumption per patient (mg)’ in Table 1, was incorrectly published as 1814.00. The correct value of ‘Total RTX consumption per patient (mg)’ should read as 11,814.00. Open Access. This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/ by-nc/4.0/), which permits any noncommercial use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

Cite

CITATION STYLE

APA

Gulácsi, L., Brodszky, V., Baji, P., Rencz, F., & Péntek, M. (2017, May 1). Erratum to: The Rituximab Biosimilar CT-P10 in Rheumatology and Cancer: A Budget Impact Analysis in 28 European Countries (Adv Ther, 10.1007/s12325-017-0522-y). Advances in Therapy. Springer Healthcare. https://doi.org/10.1007/s12325-017-0538-3

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free